Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Wolfgang Mueck"'
Autor:
Corina Becker, Michael Boettcher, Uwe Muenster, Stephanie Loewen, Maximilian Lobmeyer, Wolfgang Mueck
Publikováno v:
AAPS Open, Vol 8, Iss 1, Pp 1-14 (2022)
Abstract Objective This article describes in vitro and in vivo studies that aimed to further characterize the biopharmaceutical properties and pharmacokinetic (PK) profile of vericiguat and to guide dosing recommendations. Methods Five open-label, ph
Externí odkaz:
https://doaj.org/article/4892723d0c0347558a185457f4716204
Autor:
Alexander Solms, Matthias Frede, Scott D. Berkowitz, Anne Hermanowski‐Vosatka, Dagmar Kubitza, Wolfgang Mueck, Theodore E. Spiro, Stefan Willmann, Xiaoyu Yan, Liping Zhang, Dirk Garmann
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 805-814 (2019)
Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic (PK) data to
Externí odkaz:
https://doaj.org/article/3284b20cca0648198b411dd0ffa0f05c
Autor:
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck
Publikováno v:
Pulmonary Circulation, Vol 9 (2019)
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investig
Externí odkaz:
https://doaj.org/article/4c4d6bddaa564112b9b776fd3aaf5d66
Autor:
Rolf Burghaus, Katrin Coboeken, Thomas Gaub, Lars Kuepfer, Anke Sensse, Hans-Ulrich Siegmund, Wolfgang Weiss, Wolfgang Mueck, Joerg Lippert
Publikováno v:
PLoS ONE, Vol 6, Iss 4, p e17626 (2011)
Rivaroxaban is an oral, direct Factor Xa inhibitor approved in the European Union and several other countries for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and is in advanced clinic
Externí odkaz:
https://doaj.org/article/4973a92e090f4488af97e9bcded0d5a5
Autor:
Kenichi Yoshikawa, Wolfgang Mueck, Corina Becker, Michael Boettcher, Erich Arens, Dirk Thomas, Stephanie Loewen
Publikováno v:
European Journal of Clinical Pharmacology
Purpose To characterize the safety, pharmacodynamics, and pharmacokinetics (PK) of vericiguat in healthy males. Methods Six phase I studies were conducted in European, Chinese, and Japanese males. Subjects received oral vericiguat as a single dose (0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3af0aa5c5a3705a12944a1f6c32d9e5
https://doi.org/10.1007/s00228-020-03023-7
https://doi.org/10.1007/s00228-020-03023-7
Autor:
Alexander Solms, Stefan Willmann, Isabel Reinecke, Theodore E. Spiro, Gary Peters, Jeffrey I. Weitz, Wolfgang Mueck, Dirk Garmann, Stephan Schmidt, Liping Zhang, Keith A. A. Fox, Scott D. Berkowitz
Publikováno v:
Journal of Thrombosis and Thrombolysis
Anticoagulant plasma concentrations and patient characteristics might affect the benefit–risk balance of therapy. This study assessed the impact of model-predicted rivaroxaban exposure and patient characteristics on outcomes in patients receiving r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a11b1d7490bb0bcce36ef5d9cd7c03bd
http://europepmc.org/articles/PMC7293979
http://europepmc.org/articles/PMC7293979
Autor:
Ayoub Mounim, Wolfgang Mueck
Publikováno v:
Physical Review
We refine the calculation of holographic complexity of black holes in the complexity equals action approach by applying the recently introduced criterion that the action of any causal diamond in static vacuum regions must vanish identically. This cri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4648111f491f9adc6947b382040669af
http://hdl.handle.net/11588/869001
http://hdl.handle.net/11588/869001
Autor:
Joerg Lippert, Sebastian Schneckener, Michaela Meyer, Rolf Burghaus, Roland Loosen, Stefan Dr. Willmann, Katrin Coboeken, Wolfgang Mueck, Corina Becker
Publikováno v:
European Heart Journal. 42
Background/Introduction Vericiguat is a soluble guanylate cyclase (sGC) stimulator, like riociguat and nelociguat, and entered clinical development in 2012. Before entering Phase 2, pharmacokinetics (PK) and pharmacodynamics (PD) of vericiguat had be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf3b9a3ea02be50da3b1d49a2754bef2
https://doi.org/10.1093/eurheartj/ehab724.0919
https://doi.org/10.1093/eurheartj/ehab724.0919
Autor:
Scott D. Berkowitz, Alexander Solms, Liping Zhang, Stefan Willmann, Matthias Frede, Wolfgang Mueck, Dirk Garmann, Theodore E. Spiro, Anne Hermanowski-Vosatka, Dagmar Kubitza, Xiaoyu Yan
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 805-814 (2019)
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 805-814 (2019)
Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic (PK) data to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bcdf5afec20ec3d7c13c13f8ac4a719
http://europepmc.org/articles/PMC6875705
http://europepmc.org/articles/PMC6875705
Autor:
Wolfgang Mueck, A.O Aliprantis, Maximilian Lobmeyer, M Meyer, Michael Boettcher, Corina Becker, M Trujillo
Publikováno v:
European Heart Journal. 41
Introduction The Phase III VICTORIA study (NCT02861534), which evaluated vericiguat vs placebo in patients with worsening chronic heart failure (WCHF) with ejection fraction Purpose A comprehensive clinical pharmacological programme of 28 Phase I tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d22ef17793b1fdcfa3f44bc7f6812c8
https://doi.org/10.1093/ehjci/ehaa946.3328
https://doi.org/10.1093/ehjci/ehaa946.3328